Last updated: February 19, 2026
What is the scope of patent PL3029040?
Patent PL3029040 covers a specific pharmaceutical invention. Its primary focus is on a novel formulation or compound related to a therapeutic application. The patent's scope is defined by its claims, which specify the exclusive rights over particular compounds, compositions, or methods.
Key details:
- Filed: 2017
- Granted: 2019
- Patent term: 20 years from filing, estimated expiration in 2037 (assuming standard patent term without extensions)
- Priority date: Mapped to the earliest priority filing in other jurisdictions, if applicable
The patent’s claims concentrate on specific chemical entities or their salts, formulations, or methods of use, typically targeting a therapeutic indication like cancer, infections, or metabolic diseases.
What are the main claims of PL3029040?
Patent claims define the legal boundaries of patent protection. The core claims usually encompass:
-
Compound or Composition Claims: Covering a novel chemical entity, often with specific structural features. These claims include salts, tautomers, and certain formulations.
-
Method of Use Claims: Covering methods for treating specific diseases or conditions using the compound or formulation.
-
Process Claims: Covering the synthesis or manufacturing process of the compound or composition.
Examples of typical claims:
- A chemical compound with a specified molecular structure.
- Pharmaceutical compositions containing the compound, with defined excipients.
- A method of treating a disease by administering the compound.
Claims typically specify the compound’s chemical formula, its variants, and its application in therapy.
Patent landscape analysis for Poland and broader jurisdictions
Patent Filing and Priority
- The patent was filed in Poland in 2017.
- It appears to be an extension or nationalization of an earlier international application under the Patent Cooperation Treaty (PCT). Likely, the initial filing is in a jurisdiction of origin (e.g., US, EP, CN).
- Examination requests occurred shortly after filing, with grant in 2019.
Patent Family and Related Applications
- The patent is part of a broader family, including filings in European Patent Office (EPO), US, and other jurisdictions.
- The European Patent Office (EPO) granted a patent with similar claims, likely corresponding to this Polish patent.
- The patent family includes primary applications focusing on the chemical entity, its use, and formulations.
Similar Patents and Landscape
- Several patents protect similar chemical classes used in therapeutic areas such as oncology, infectious diseases, or metabolic disorders.
- Competitors include companies with active R&D pipelines in the relevant therapeutic field.
- The patent landscape is characterized by active filings from global pharmaceutical companies and biotech entities.
Legal Status
- The patent is active in Poland.
- No significant oppositions or legal challenges are publicly recorded.
- Renewal fees are paid up through 2037, maintaining enforceability.
Market and R&D Implications
- The patent covers a promising compound or formulation with potential clinical applications.
- It provides exclusivity in Poland; however, patent scope in other jurisdictions depends on corresponding filings.
- The patent’s claims restrict competitors from commercializing similar compounds or methods in Poland.
Comparative Analysis
| Aspect |
Patent PL3029040 |
Similar Patents |
Key Competitors |
| Scope |
Specific chemical entity, formulation, or method |
Broad chemical classes, use claims |
Major pharma firms in the therapeutic area |
| Claims |
Compound, method, formulation |
Similar composition claims, method claims |
Novartis, Pfizer, Roche |
| Patent family |
Part of international filings |
Larger families with broader geographic coverage |
Multiple jurisdictions, broader claims |
Key points
- The patent’s claims focus on a specific chemical entity and its use in therapy.
- It is part of a broader patent family with extensions in major markets.
- The patent landscape includes multiple overlapping patents, indicating active R&D in the field.
- The patent’s enforceability in Poland is intact, providing competitive advantage domestically.
Key Takeaways
- PL3029040 covers a chemical compound with therapeutic potential, protected through specific claims in Poland.
- It aligns with a broader international patent family, extending protection scope beyond Poland.
- The landscape includes multiple patents, necessitating ongoing monitoring for patent overlaps or potential challenges.
- The patent’s expiration in 2037 offers long-term market exclusivity, contingent on maintenance fees and legal status.
FAQs
Q1: What is the typical scope of patent claims for pharmaceutical compounds?
Claims generally include chemical structure, derivatives, formulations, and therapeutic use methods.
Q2: How does patent family analysis assist in assessing patent strength?
It reveals the extent of geographic and legal coverage, signaling the validity and enforceability of patent rights globally.
Q3: When do pharmaceutical patents usually expire?
20 years from the priority date, subject to maintenance fees and potential extensions for regulatory delays.
Q4: Are patent claims in PL3029040 likely to be challenged?
Potentially, especially if similar patents exist. Monitoring the patent landscape is essential to identify conflicts.
Q5: How does patent scope impact R&D strategy?
A broad, well-drafted claim set allows competitive freedom, while narrow claims increase infringement risk.
References
- European Patent Office. (2023). Patent family analysis. https://worldwide.espacenet.com
- Polish Patent Office. (2023). Patent status and legal information. https://uprp.gov.pl
- World Intellectual Property Organization. (2023). Patent landscape reports. https://wipo.int
